Clinical Trial Update: Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of vildagliptin for treating antipsychotic-induced dyslipidemia in schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Schizophrenia

Drugs mentioned

• Vildagliptin (Galvus) (vildagliptin)

Snippet

Sponsor: Sadat City University | Conditions: Schizophrenia, Dyslipidemias | Phase 2 | Status: WITHDRAWN